Search
Results: 17
Spotlight on landmark oncology trials
The era of precision oncology is marked with prominent successes in the therapy of advanced soft tissue sarcomas, breast cancer, ovarian cancer and haematological neoplasms, among others. Moreover, recent trials of immune...
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
BACKGROUND: Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness...
biomarker Cancer Companion biomarker Companion diagnostic cost-effectiveness economic evaluation health economics oncology Precision Medicine Systematic review targeted therapy Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Cost-Benefit Analysis Humans Molecular Targeted Therapy Neoplasms Precision Medicine Prognosis ROC Curve Survival Rate
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Sandra Cantilena, Luca Gasparoli, Deepali Pal, Olaf Heidenreich, Jan-Henning Klusmann, Joost HA Martens, Alexandre Faille, Alan J Warren, Mawar Karsa, Ruby Pandher, Klaartje Somers, Owen Williams, Jasper de Boer
Jul 22, 2022
BACKGROUND: Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein-driven paediatric cancer, with MLL (KMT2A)-fusions present in most cases. Direct...
Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias
Sandra Cantilena, Luca Gasparoli, Deepali Pal, Olaf Heidenreich, Jan‐Henning Klusmann, Joost HA Martens, Alexandre Faille, Alan J Warren, Mawar Karsa, Ruby Pandher, Klaartje Somers, Owen Williams, Jasper de Boer
Jun 29, 2022
Abstract: Background: Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein‐driven paediatric cancer, with MLL (KMT2A)‐fusions present in most cases....
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Lorenzo Marconi, Roderick de Bruijn, Erik Van Werkhoven, Christian Beisland, Kate Fife, Axel Heidenreich, Anil Kapoor, Jose Karam, Caroline Kauffmann, Tobias Klatte, Boerje Ljungberg, Surena Matin, Daniel Sjoberg, Michael Staehler, Grant D Stewart, Simon Tanguay, Robert Uzzo, Sarah Welsh, Lori Wood, Chris Wood, Axel Bex
Sep 08, 2018
INTRODUCTION: Recent trials have emphasized the importance of a precise patient selection for cytoreductive nephrectomy (CN). In 2013, a nomogram was developed for pre- and postoperative prediction of the probability of death...
cytoreductive nephrectomy Metastatic renal cancer Nomogram selection targeted therapy validation Adrenal Gland Neoplasms Aged Antineoplastic Agents Area Under Curve Blood Transfusion Bone Neoplasms Brain Neoplasms Carcinoma Renal Cell Cytoreduction Surgical Procedures Female Humans Intraoperative Care Kaplan-Meier Estimate Kidney Neoplasms L-Lactate Dehydrogenase Liver Neoplasms Lung Neoplasms Male Middle Aged Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging Nephrectomy Nomograms Patient Selection Prognosis Reproducibility of Results Serum Albumin Survival Rate
Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells
Glioblastoma (GBM) is an aggressive tumor of the central nervous system categorized by the World Health Organization as a Grade 4 astrocytoma. Despite treatment with surgical resection, adjuvant chemotherapy, and radiation...
BRCA1-like signature in triple negative breast cancer
Tesa M Severson, Justine Peeters, Ian Majewski, Magali Michaut, Astrid Bosma, Philip C Schouten, Suet-Feung Chin, Bernard Pereira, Mae A Goldgraben, Tycho Bismeijer, Roelof JC Kluin, Jettie JF Muris, Karin Jirström, Ron M Kerkhoven, Lodewyk Wessels, Carlos Caldas, René Bernards, Iris M Simon, Sabine Linn
Jul 05, 2018
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are mutant for the tumor suppressor, BRCA1. BRCA1 is required for homologous recombination-mediated DNA repair and deficiency...
BRCA1 Breast Cancer Genomic Instability targeted therapy Triple negative breast cancer Adult Aged Aged 80 and over Comparative Genomic Hybridization DNA Methylation DNA Mutational Analysis Female Gene Expression Profiling Gene Expression Regulation Neoplastic Genes BRCA1 High-Throughput Nucleotide Sequencing Humans Microarray Analysis Middle Aged Molecular Targeted Therapy Promoter Regions Genetic Transcriptome Triple Negative Breast Neoplasms
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Keith I Block, Charlotte Gyllenhaal, Leroy Lowe, Amedeo Amedei, ARM Ruhul Amin, Amr Amin, Katia Aquilano, Jack Arbiser, Alexandra Arreola, Alla Arzumanyan, S Salman Ashraf, Asfar S Azmi, Fabian Benencia, Dipita Bhakta, Alan Bilsland, Anupam Bishayee, Stacy W Blain, Penny B Block, Chandra S Boosani, Thomas E Carey, Amancio Carnero, Marianeve Carotenuto, Stephanie C Casey, Mrinmay Chakrabarti, Rupesh Chaturvedi, Georgia Zhuo Chen, Helen Chen, Sophie Chen, Yi Charlie Chen, Beom K Choi, Maria Rosa Ciriolo, Helen M Coley, Andrew R Collins, Marisa Connell, Sarah Crawford, Colleen S Curran, Charlotta Dabrosin, Giovanna Damia, Santanu Dasgupta, Ralph J DeBerardinis, William K Decker, Punita Dhawan, Anna Mae E Diehl, Jin-Tang Dong, Q Ping Dou, Janice E Drew, Eyad Elkord, Bassel El-Rayes, Mark A Feitelson, Dean W Felsher, Lynnette R Ferguson, Carmela Fimognari, Gary L Firestone, Christian Frezza, Hiromasa Fujii, Mark M Fuster, Daniele Generali, Alexandros G Georgakilas, Frank Gieseler, Michael Gilbertson, Michelle F Green, Brendan Grue, Gunjan Guha, Dorota Halicka, William G Helferich, Petr Heneberg, Patricia Hentosh, Matthew D Hirschey, Lorne J Hofseth, Randall F Holcombe, Kanya Honoki, Hsue-Yin Hsu, Gloria S Huang, Lasse D Jensen, Wen G Jiang, Lee W Jones, Phillip A Karpowicz, W Nicol Keith, Sid P Kerkar, Gazala N Khan, Mahin Khatami, Young H Ko, Omer Kucuk, Rob J Kulathinal, Nagi B Kumar, Byoung S Kwon, Anne Le, Michael A Lea, Ho-Young Lee, Terry Lichtor, Liang-Tzung Lin, Jason W Locasale, Bal L Lokeshwar, Valter D Longo, Costas A Lyssiotis, Karen L MacKenzie, Meenakshi Malhotra, Maria Marino, Maria L Martinez-Chantar, Ander Matheu, Christopher Maxwell, Eoin McDonnell, Alan K Meeker, Mahya Mehrmohamadi, Kapil Mehta, Gregory A Michelotti, Ramzi M Mohammad, Sulma I Mohammed, D James Morre, Vinayak Muralidhar, Irfana Muqbil, Michael P Murphy, Ganji Purnachandra Nagaraju, Rita Nahta, Elena Niccolai, Somaira Nowsheen, Carolina Panis, Francesco Pantano, Virginia R Parslow, Graham Pawelec, Peter L Pedersen, Brad Poore, Deepak Poudyal, Satya Prakash, Mark Prince, Lizzia Raffaghello, Jeffrey C Rathmell, W Kimryn Rathmell, Swapan K Ray, Jörg Reichrath, Sarallah Rezazadeh, Domenico Ribatti, Luigi Ricciardiello, R Brooks Robey, Francis Rodier, HP Vasantha Rupasinghe, Gian Luigi Russo, Elizabeth P Ryan, Abbas K Samadi, Isidro Sanchez-Garcia, Andrew J Sanders, Daniele Santini, Malancha Sarkar, Tetsuro Sasada, Neeraj K Saxena, Rodney E Shackelford, HMC Shantha Kumara, Dipali Sharma, Dong M Shin, David Sidransky, Markus David Siegelin, Emanuela Signori, Neetu Singh, Sharanya Sivanand, Daniel Sliva, Carl Smythe, Carmela Spagnuolo, Diana M Stafforini, John Stagg, Pochi R Subbarayan, Tabetha Sundin, Wamidh H Talib, Sarah K Thompson, Phuoc T Tran, Hendrik Ungefroren, Matthew G Vander Heiden, Vasundara Venkateswaran, Dass S Vinay, Panagiotis J Vlachostergios, Zongwei Wang, Kathryn E Wellen, Richard L Whelan, Eddy S Yang, Huanjie Yang, Xujuan Yang, Paul Yaswen, Clement Yedjou, Xin Yin, Jiyue Zhu, Massimo Zollo
Feb 16, 2016
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review
Abstract: Background: Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different...
Repurposing hyperpolarization-activated cyclic nucleotide-gated channels as a novel therapy for breast cancer.
Ka-Chun Mok, Ho Tsoi, Ellen PS Man, Man-Hong Leung, Ka Man Chau, Lai-San Wong, Wing-Lok Chan, Sum-Yin Chan, Mai-Yee Luk, Jessie YW Chan, Jackie KM Leung, Yolanda HY Chan, Sellma Batalha, Virginia Lau, David CW Siu, Terence KW Lee, Chun Gong, Ui-Soon Khoo
Nov 04, 2021
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are members of the voltage-gated cation channel family known to be expressed in the heart and central nervous system. Ivabradine, a small molecule HCN...
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Jiaqi Li, Jie Qing Eu, Li Ren Kong, Lingzhi Wang, Yaw Chyn Lim, Boon Cher Goh, Andrea LA Wong
Oct 21, 2020
Targeting altered tumour metabolism is an emerging therapeutic strategy for cancer treatment. The metabolic reprogramming that accompanies the development of malignancy creates targetable differences between cancer cells and...
Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells
Glioblastoma (GBM) is an aggressive tumor of the central nervous system categorized by the World Health Organization as a Grade 4 astrocytoma. Despite treatment with surgical resection, adjuvant chemotherapy, and radiation...
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
Dana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, Oscar M Rueda, Christopher G Smith, Dineika Chandrananda, Ross A Soo, Hong Liang Lim, Boon Cher Goh, Carlos Caldas, Tim Forshew, Davina Gale, Wei Liu, James Morris, Francesco Marass, Tim Eisen, Tan Min Chin, Nitzan Rosenfeld
Aug 15, 2018
Circulating tumour DNA Liquid biopsy Lung cancer resistance mechanisms targeted therapy Antineoplastic Agents Carcinoma Non-Small-Cell Lung DNA Copy Number Variations DNA Mutational Analysis DNA Neoplasm Drug Resistance Neoplasm ErbB Receptors Gefitinib Humans Hydroxychloroquine Longitudinal Studies Lung Neoplasms Mutation Prognosis Survival Analysis Treatment Outcome Tumor Suppressor Protein p53
Molecular Landscape of Acute Myeloid Leukemia
PURPOSE OF REVIEW: The field of acute myeloid leukemia (AML) has been revolutionized in recent years by the advent of high-throughput techniques, such as next-generation sequencing. In this review, we will discuss some of the...